[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
June 2016

Driving Eligibility in Proliferative Diabetic Retinopathy

Author Affiliations
  • 1Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham
  • 2Department of Epidemiology, School of Public Health, University of Alabama at Birmingham
JAMA Ophthalmol. 2016;134(6):672-673. doi:10.1001/jamaophthalmol.2016.0562

In this issue of JAMA Ophthalmology, Subash et al1 report that most of their study participants who underwent bilateral multispot laser panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) met the visual field standard for holding a car or motorcycle license in the United Kingdom 6 months after treatment. As the authors point out, although PRP has been shown to reduce the risk for severe visual loss from PDR, the treatment can come at a cost to peripheral vision, namely, loss of peripheral light sensitivity. In this study, the authors document some loss of peripheral vision; however, 35 of the 38 available participants (92%) met the United Kingdom’s visual field requirement for licensure 6 months after treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×